zl-82
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 9, 2023 (NCT06055023)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07193589 | Phase 2 | Oct 30, 2025 | Government of China |
| NCT06432738 | Phase 1 | Mar 1, 2024 | Government of China |
| NCT06055023 | Phase 1 | Apr 9, 2023 | Government of China, Sichuan University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 3 | 3 | 2 | 2023 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1